SCHEMBL12540

SCHEMBL12540

Cc1ccc2[nH]c(C)nc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.50
MAPT P10636 4/20 0.46
KMT2A Q03164 4/20 0.46
CYP1A2 P05177 3/20 0.46
MEN1 O00255 2/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
POLB P06746 3/20 0.46
HPGD P15428 2/20 0.46
KDM4E B2RXH2 2/20 0.46
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HSP90AA1 P07900 1/20 0.44
ESR2 Q92731 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
NQO2 P16083 1/20 0.43
GAA P10253 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CA12 O43570 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15477598 0.92 ALDH1A1 (0.58) ALDH1A1MAPTKMT2ACYP1A2MEN1
SCHEMBL29727934 0.83 ALDH1A1 (0.66) ALDH1A1MAPTKMT2ACYP1A2MEN1
SCHEMBL25457211 0.83 RAB9A (0.53) ALDH1A1MAPTKMT2AMEN1POLB
SCHEMBL266609 0.83 ALDH1A1 (0.66) ALDH1A1MAPTKMT2ACYP1A2MEN1
SCHEMBL1171203 0.83 NPC1 (0.51) ALDH1A1MAPTKMT2ACYP1A2MEN1
SCHEMBL12052868 0.81 POLB (0.51) ALDH1A1MAPTKMT2AMEN1POLB
SCHEMBL2756728 0.80 ALDH1A1 (0.49) ALDH1A1MAPTKMT2ACYP1A2MEN1
SCHEMBL26039239 0.80 ALDH1A1 (0.41) ALDH1A1MAPTKMT2AMEN1POLB
SCHEMBL12930776 0.80 ALDH1A1 (0.50) ALDH1A1MAPTKMT2AMEN1CYP2C9
SCHEMBL229607 0.79 KMT2A (0.44) ALDH1A1MAPTKMT2ACYP1A2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 927 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163322-A1 ETCHING COMPOSITION AND METHOD FOR PRODUCING WIRING BOARD USING SAME MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2025-05-22 US claimed
US-9486892-B2 Polishing composition FUJIMI INCORPORATED (JP) 2016-11-08 US claimed
EP-1976829-A2 N-(6-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS GENELABS TECHNOLOGIES, INC. (US) 2008-10-08 EP claimed
US-20070265262-A1 N-(6-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS GENELABS TECHNOLOGIES, INC. 2007-11-15 US claimed
WO-2007070556-A2 N-(6-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS GENELABS TECHNOLOGIES, INC. (US) 2007-06-21 WO claimed
US-20250163322-A1 ETCHING COMPOSITION AND METHOD FOR PRODUCING WIRING BOARD USING SAME MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2025-05-22 US disclosed
US-20240400401-A1 USE OF CATIONS SELECTED FROM 1,2,3,5-TETRAMETHYL-BENZIMIDAZOLIUM, 1,2,3,4,5-PENTAMETHYLBENZIMIDAZOLIUM, AND 1,2,3,4,6-PENTAMETHYLBENZIMIDAZOLIUM AS STRUCTURE DIRECTING AGENTS FOR THE PREPARATION OF MOLECULAR SIEVES AND MOLECULAR SIEVES OBTAINED USING THE SAME ExxonMobil Technology and Engineering Company 2024-12-05 US disclosed
EP-4400505-A1 PEPTIDE-UREA DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND APPLICATION THEREOF Bivision Pharmaceuticals, Inc (CN) 2024-07-17 EP disclosed
EP-4398362-A1 POLYMER SOLID ELECTROLYTE AND APPLICATION Nanjing Bochi New Energy Co., Ltd. (CN) 2024-07-10 EP disclosed
WO-2024130689-A1 2-FLUOROBIPHENYL-4-ACETIC ACID DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF 江苏普莱医药生物技术有限公司 2024-06-27 WO disclosed
US-11992914-B2 Polishing composition, polishing method, and method for producing substrate FUJIMI INCORPORATED (JP) 2024-05-28 US disclosed
WO-2024039858-A1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF OLEMA PHARMACEUTICALS, INC. (US) 2024-02-22 WO disclosed
WO-2005002552-A2 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2005-01-13 WO disclosed
US-20040220208-A1 Imidazopyridinones as p38 map kinase inhibitors BAYER HEALTHCARE AG (DE) 2004-11-04 US disclosed
EP-1412353-A1 IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS Bayer HealthCare AG (DE) 2004-04-28 EP disclosed
WO-2003008413-A1 IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS BAYER HEALTHCARE AG (DE) 2003-01-30 WO disclosed
EP-0734386-B1 PLATELET ACTIVATING FACTOR ANTAGONISTS: IMIDAZOPYRIDINE INDOLES ABBOTT LAB (US) 2002-02-06 EP disclosed
EP-0734386-A1 PLATELET ACTIVATING FACTOR ANTAGONISTS: IMIDAZOPYRIDINE INDOLES Abbott Laboratories (US) 1996-10-02 EP disclosed
US-5486525-A ANTIINFLAMMATORY AGENTS ABBOTT LABORATORIES (US) 1996-01-23 US disclosed
WO-1995016687-A1 PLATELET ACTIVATING FACTOR ANTAGONISTS: IMIDAZOPYRIDINE INDOLES ABBOTT LABORATORIES (US) 1995-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220208-A1 Imidazopyridinones as p38 map kinase inhibitors MAPK1, MAPK3, MAP3K1 ALDH1A1 1216/4885MAPT 1617/4885KMT2A 2453/4885
US-20070265262-A1 N-(6-MEMBERED AROMATIC RING)-AMIDO ANTI-VIRAL COMPOUNDS ZC3HAV1, HAVCR2, ZC3HAV1L ALDH1A1 4167/4885MAPT 1728/4885KMT2A 2578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.